| Dr Alan M Sanders, MD | |
|
404 New Scotland Ave, Albany, NY 12208-2725 | |
| (518) 435-0662 | |
| (518) 435-0664 |
| Full Name | Dr Alan M Sanders |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 36 Years |
| Location | 404 New Scotland Ave, Albany, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952340523 | NPI | - | NPPES |
| 18N901 | Other | NY | BLUE CROSS |
| 000402901001 | Other | NY | BLUE SHIELD |
| 10001789 | Other | NY | CDPHP |
| 01487796 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 181447 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Albany Medical Center Hospital | Albany, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Albany Medical College | 1759293111 | 910 |
News Archive
Novian Health, developer of Novilase® Breast Therapy, announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval for the company to start a multi-center study of its Novilase® Interstitial Laser Therapy (ILT) System. Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors.
A tool to predict the risk of readmission to hospital or death in the first year after leaving hospital for adult survivors of sepsis has been developed by a researcher at King's.
The scientific journal Addiction has today published a collection of peer-reviewed research papers and commentaries that bring together key parts of the evidence base for standardised packaging of tobacco products from 2008 to 2015.
Although, bacteria are a critical etiologic factor that are needed to develop periodontal disease, bacteria alone are insuficiente to induce a periodontal disease. A susceptible host is also required, and the host's susceptibility as local and/or general predisposing risk factors, are important determinants of the disease status.
› Verified 9 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629008537 PECOS PAC ID: 1759293111 Enrollment ID: O20031125000386 |
News Archive
Novian Health, developer of Novilase® Breast Therapy, announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval for the company to start a multi-center study of its Novilase® Interstitial Laser Therapy (ILT) System. Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors.
A tool to predict the risk of readmission to hospital or death in the first year after leaving hospital for adult survivors of sepsis has been developed by a researcher at King's.
The scientific journal Addiction has today published a collection of peer-reviewed research papers and commentaries that bring together key parts of the evidence base for standardised packaging of tobacco products from 2008 to 2015.
Although, bacteria are a critical etiologic factor that are needed to develop periodontal disease, bacteria alone are insuficiente to induce a periodontal disease. A susceptible host is also required, and the host's susceptibility as local and/or general predisposing risk factors, are important determinants of the disease status.
› Verified 9 days ago
| Entity Name | Albany Medical College |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497921688 PECOS PAC ID: 1759293111 Enrollment ID: O20190320001621 |
News Archive
Novian Health, developer of Novilase® Breast Therapy, announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval for the company to start a multi-center study of its Novilase® Interstitial Laser Therapy (ILT) System. Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors.
A tool to predict the risk of readmission to hospital or death in the first year after leaving hospital for adult survivors of sepsis has been developed by a researcher at King's.
The scientific journal Addiction has today published a collection of peer-reviewed research papers and commentaries that bring together key parts of the evidence base for standardised packaging of tobacco products from 2008 to 2015.
Although, bacteria are a critical etiologic factor that are needed to develop periodontal disease, bacteria alone are insuficiente to induce a periodontal disease. A susceptible host is also required, and the host's susceptibility as local and/or general predisposing risk factors, are important determinants of the disease status.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alan M Sanders, MD 32 Carstead Dr, Slingerlands, NY 12159-9792 Ph: (518) 435-0662 | Dr Alan M Sanders, MD 404 New Scotland Ave, Albany, NY 12208-2725 Ph: (518) 435-0662 |
News Archive
Novian Health, developer of Novilase® Breast Therapy, announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval for the company to start a multi-center study of its Novilase® Interstitial Laser Therapy (ILT) System. Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors.
A tool to predict the risk of readmission to hospital or death in the first year after leaving hospital for adult survivors of sepsis has been developed by a researcher at King's.
The scientific journal Addiction has today published a collection of peer-reviewed research papers and commentaries that bring together key parts of the evidence base for standardised packaging of tobacco products from 2008 to 2015.
Although, bacteria are a critical etiologic factor that are needed to develop periodontal disease, bacteria alone are insuficiente to induce a periodontal disease. A susceptible host is also required, and the host's susceptibility as local and/or general predisposing risk factors, are important determinants of the disease status.
› Verified 9 days ago
Arunima Rajbhandary, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 315 S Manning Blvd, Albany, NY 12208 Phone: 518-525-1550 | |
Dr. Rahul Ravilla, M.D Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 43 New Scotland Ave Ste 7, Albany, NY 12208 Phone: 518-262-6696 Fax: 518-262-2624 | |
Emmanuelle Cordero Torres, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 47 New Scotland Ave Dept Of Nephrology, Albany Medical Center, Albany, NY 12208 Phone: 518-262-5377 | |
Nancy Shrestha, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 5 Palisades Dr Ste 200, Albany, NY 12205 Phone: 518-471-3636 Fax: 518-471-3668 | |
Stephen Hillinger, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 400 Patroon Creek Blvd, Suite 1, Albany, NY 12206 Phone: 518-489-0044 Fax: 518-489-3591 | |
Louis H Gold, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5 Palisades Dr, Ste100, Albany, NY 12205 Phone: 518-438-4496 | |
Sean Joseph Sheehan, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1375 Washington Ave, Suite 101, Albany, NY 12206 Phone: 518-438-4483 Fax: 518-482-4201 |